ENDOMETRIAL ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug combo aims to shrink endometrial tumors
Disease control Recruiting nowThis Phase 2 trial tests an experimental drug called ACR-368, alone or with a low dose of gemcitabine, in 350 people with high-grade endometrial cancer. A special test (OncoSignature) helps decide which treatment arm a participant joins. The main goal is to see if the drug shrink…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:58 UTC
-
Immunotherapy duo shows promise against tough uterine cancer
Disease control Recruiting nowThis study is for people with recurrent endometrial cancer that has a specific DNA repair problem (called dMMR). It compares a combination of two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone to see which shrinks tumors better. About 81 participants will …
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:52 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control Recruiting nowThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Matched conditions: ENDOMETRIAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC